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Abstract
Background: Subclinical hypothyroidism is common in older people and its contribution to health and disease
needs to be elucidated further. Observational and clinical trial data on the clinical effects of subclinical
hypothyroidism in persons aged 80 years and over is inconclusive, with some studies suggesting harm and some
suggesting benefits, translating into equipoise whether levothyroxine therapy provides clinical benefits. This
manuscript describes the study protocol for the Institute for Evidence-Based Medicine in Old Age (IEMO) 80-plus
thyroid trial to generate the necessary evidence base.
Methods: The IEMO 80-plus thyroid trial was explicitly designed as an ancillary experiment to the Thyroid hormone
Replacement for Untreated older adults with Subclinical hypothyroidism randomised placebo controlled Trial
(TRUST) with a near identical protocol and shared research infrastructure. Outcomes will be presented separately for
the IEMO and TRUST 80-plus groups, as well as a pre-planned combined analysis of the 145 participants included in
the IEMO trial and the 146 participants from the TRUST thyroid trial aged 80 years and over.
The IEMO 80-plus thyroid trial is a multi-centre randomised double-blind placebo-controlled parallel group trial of
levothyroxine treatment in community-dwelling participants aged 80 years and over with persistent subclinical
hypothyroidism (TSH ≥4.6 and ≤ 19.9 mU/L and fT4 within laboratory reference ranges). Participants are randomised
to levothyroxine 25 or 50 micrograms daily or matching placebo with dose titrations according to TSH levels, for a
minimum follow-up of one and a maximum of three years.
Primary study endpoints: hypothyroid physical symptoms and tiredness on the thyroid-related quality of life
patient-reported outcome (ThyPRO) at one year. Secondary endpoints: generic quality of life, executive
cognitive function, handgrip strength, functional ability, blood pressure, weight, body mass index, and
mortality. Adverse events will be recorded with specific interest on cardiovascular endpoints such as atrial
fibrillation and heart failure.
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Discussion: The combined analysis of participants in the IEMO 80-plus thyroid trial with the participants aged
over 80 in the TRUST trial will provide the largest experimental evidence base on multimodal effects of
levothyroxine treatment in 80-plus persons to date.
Trial registration: Nederlands (Dutch) Trial Register: NTR3851 (12–02-2013), EudraCT: 2012–004160-22 (17–02-2013),
ABR-41259.058.13 (12–02-2013).
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Background
Subclinical hypothyroidism (SCH) is a common aberrant
biochemical finding defined as an elevated serum
thyroid-stimulating hormone (TSH) and normal circulat-
ing thyroid hormone level [1]. SCH is associated with
multiple health problems in old age ranging from mild
non-specific symptoms such as tiredness and emotional
susceptibility to coronary heart disease and decreased
physical and cognitive functioning [2].
As 8–18% of those over 65 years are affected and infer-
ence from both observational and experimental studies
maintain the clinical equipoise whether the merits of
levothyroxine treatment outweigh the risks [3], the Thy-
roid hormone Replacement for Untreated older adults
with Subclinical hypothyroidism randomised placebo con-
trolled Trial (TRUST) [4] was designed to resolve this
clinical uncertainty. The outcomes of the TRUST trial
provided robust information that for community-dwelling
persons of 65 years of age and older with SCH, levothyr-
oxine treatment provides no apparent benefits [4].
There are ample data to suggest that thyroid function is
mediated by age and that the effects of SCH may be pro-
foundly different in octogenarians and older [3]. Older
persons generally require different dosages of levothyrox-
ine to achieve euthyroidism than younger counterparts
possibly due to changes in body weight, composition or
hormonal status [5] and are at higher risk of adverse ef-
fects of overtreatment including cardiovascular events, ar-
rhythmias and fractures [6]. In a large-scale, observational
follow-up study among 599 community-dwelling partici-
pants aged 85 years and over, increasing levels of TSH
were associated with prolonged life span [7]. This associ-
ation, however, could not be confirmed in a later Individ-
ual Patient Data meta-analysis investigating mortality
information in 4344 participants with SCH aged 80 years
and over [8]. In addition, members of families with excep-
tional longevity are characterized by slightly higher TSH
and slightly lower circulating thyroid hormone levels
when compared with the general population [9].
To help resolve this clinical uncertainty of levothyroxine
replacement treatment for SCH in older persons, we have
performed an randomized controlled trial including par-
ticipants over 80 years old in the presence of comorbid
conditions; the Institute for Evidence-Based Medicine in
Old Age (IEMO)80-plus thyroid trial. The TRUST trial
was not designed specifically to investigate the effects in
80-plus participants and was consequently inadequately
powered for a subgroup analysis in participants aged 80
and over. The IEMO 80-plus thyroid trial was designed
jointly with the TRUST trial as an ancillary trial using the
same trial infrastructure and protocol to allow a
pre-planned, joint analysis of all participants aged 80 and
over. This combined endeavour will provide experimental
evidence on potential multimodal effects of levothyroxine
treatment from the largest sample of 80-plus persons with
SCH to date.
Among the specific study objectives are:
1. Does levothyroxine treatment for SCH provide
benefits for 80-plus persons with SCH?
2. Are benefits seen across a wide range of outcomes,
including health-related quality of life, muscle func-
tion, cognition and prevention of cardiovascular
disease?
3. Are benefits seen in specific subgroups of people
with SCH, including women, and those with mild
degrees of SCH (TSH 4.6–10 mU/L)?
4. Are any benefits offset by adverse effects, such as
atrial fibrillation or heart failure?
Methods and design
The IEMO 80-plus thyroid trial was designed as an ancil-
lary randomised double-blind placebo-controlled parallel
group trial of levothyroxine for persons over 80 years with
subclinical hypothyroidism. From the outset the study was
designed jointly and in parallel with the TRUST trial (de-
tails provided elsewhere [10]) and both trials share a near
identical design and infrastructure including study proto-
cols, standard operating procedures, independent data
monitoring and endpoint committees, databases, statisti-
cians and study nurses.
Initially, the IEMO 80-plus thyroid trial aimed to in-
clude 450 participants. Additionally, a pre-planned com-
bined analysis with the data from all 80-plus participants
from the TRUST trial, resulting in a total of 900 partici-
pants in the final pooled analyses, was conceived to
maximise statistical power. During the inclusion phase,
it became apparent that the proposed target of 450
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80-plus participants was unfeasible within the allotted
study period (mirroring the experiences of the TRUST
trial [10]) and revised power calculations were proposed
with the new projected target of 145 IEMO 80-plus trial
participants (see Sample size calculation).
Originally the trial was executed in 4 regions of the
Netherlands (Leiden University Medical Center, Erasmus
University Medical Center, University Medical Center
Groningen and the University of Amsterdam). During
the inclusion period, in an attempt to maximise the in-
clusion rate, organisational changes were accepted allow-
ing for inclusion of participants from all locations within
the Netherlands, coordinated by the Leiden University
Medical Center. Additionally, because the trial infra-
structure was already in place for the TRUST trial, add-
itional participants were recruited from the University
Hospital Bern in Switzerland.
Study population
One hundred forty five community-dwelling participants
≥80 years with SCH are recruited. Similar to TRUST,
participants are identified from clinical and primary care
laboratory databases from all patients having biochem-
ical features consistent with SCH. SCH is defined as per-
sistently elevated TSH levels (≥ 4.6 and ≤ 19.9 mU/L),
measured on a minimum of two occasions at least
3 months and no more than 3 years apart prior to enrol-
ment and free thyroxine (fT4) within the laboratory ref-
erence range. All participants gave written individual
informed consent to participate.
Exclusion criteria
 Participants currently on levothyroxine, antithyroid
medication (including carbimazole, methimazole,
propylthiouracil and potassium perchlorate),
amiodarone or lithium.
 Recent thyroid surgery or radio-iodine therapy
(within 12 months).
 Grade IV NYHA heart failure.
 Prior clinical diagnosis of dementia.
 Recent hospitalisation for major illness (within
4 weeks).
 Recent acute coronary syndrome, including myocardial
infarction or unstable angina (within 4 weeks).
 Acute myocarditis or acute pancarditis
 Untreated adrenal insufficiency or adrenal disorder
 Terminal illness.
 Patients known to have rare hereditary problem of
galactose intolerance.
 Participants who are participating in ongoing RCTs of
therapeutic interventions (including clinical trials of
investigational medicinal products [CTIMPs])
 Plan to move out of the region in which the trial is
being conducted within the next 2 years.
Intervention
The investigational medicinal products are levothyroxine
sodium (T4) as 25 or 50 microgram tablets for oral ad-
ministration and a matching placebo. All tablets are
white and round in shape with the strength imprinted,
identically packaged in blisters and packed in plain card-
board cartons to maintain study blinding. Participants
are advised to take the suggested dose of study medica-
tion once daily half an hour before breakfast.
The intervention group will start with levothyroxine
50 micrograms daily (25 micrograms in participants with
< 50 kg body weight or with a history of coronary heart
disease) and the control group with matching placebo
for six to 8 weeks.
After 6–8 weeks a venous blood sample is taken for
TSH assessment. Based on the TSH results, the data
centre advises the new dose of study medication or pla-
cebo to the clinical investigators.
 If TSH < 0.4 mU/L: the treatment dose is reduced to
25 micrograms levothyroxine in those starting on 50
micrograms; reduced to 0 in those starting on 25
micrograms – effected by giving placebo matching the
25 micrograms dose. These participants will have a
further TSH check after 6–8 weeks. If TSH remains
< 0.4 mU/L participant will be withdrawn from
randomised treatment and referred to usual care.
 If TSH ≥ 0.4 and < 4.6 mU/L: no change to the
treatment dose.
 If TSH remains elevated (≥ 4.6 mU/L): 25
micrograms of levothyroxine will be added. Giving a
total daily dose of 75 micrograms levothyroxine for
those starting on 50 micrograms, or a total daily
dose of 50 micrograms levothyroxine for those
starting on 25 micrograms.
A maximum of two levothyroxine up-titrations at the
start of the trial and one up-titration at 12 and 24 month
(± 1 month) intervals with repeated TSH measurements
after 6–8 weeks ensure adequate levothyroxine treatment
while avoiding potential over-replacement. The maximum
possible dose of levothyroxine is 150 micrograms.
A mock titration adopting an adaptive schedule is per-
formed in the placebo group by the data centre. A simi-
lar proportion of placebo patients will have up and
down titrations of study medication as the intervention
group to ensure the number of tablets and assessments
is similar in both groups.
Because all thyroid function measurements are avail-
able only to the data centre, the clinical investigators
remain fully blinded to the treatment allocation process
during the trial.
Accountability logs recording the quantities of study
medication dispensed to and returned from study
Du Puy et al. BMC Endocrine Disorders  (2018) 18:67 Page 3 of 14
participants, batch numbers and expiry dates are avail-
able for all study drug movements.
Criteria for discontinuing or modifying allocated study
medication:
 If overt biochemical hypothyroidism is identified
(TSH > 20 mU/L and/or fT4 below the reference
range) a second TSH with fT4 within 2 weeks is
requested. Upon confirmation of biochemical
hypothyroidism the participant will be withdrawn
from the study treatment and referred to the
General Practitioner (GP) for usual care.
 If overt biochemical hyperthyroidism is identified
(TSH < 0.4 mU/L) in the placebo group, or
consecutively in the treatment group despite
downtitrations, the participant will be withdrawn
from the study treatment and referred to the GP for
usual care.
 If for clinical reasons (e.g. major illness) a proposed
change in study medication or placebo is deemed
inappropriate the algorithm is overridden by the
local principal coordinator and no change in study
medication takes place.
Randomisation
Participants are randomised to either the levothyroxine
or placebo treatment arm (ratio 1:1) using the randomly
permuted block method, stratified by site, sex and start-
ing dose. The data centre (Robertson Centre for Biostat-
istics, University of Glasgow, Scotland) independently
provides the randomisation schedule. Mawdsley Brooks
& Co. implements the schedule through identical pack-
aging of levothyroxine and matching placebo tablets.
Patient allocation is conducted via the dedicated trial
web portal by the study nurses. When a participant is
eligible based on entering the eligibility criteria in an
electronic case report form (eCRF) supervised by a med-
ically certified Principle Investigator, a central computer
will trigger the decision.
Blinding
Participants are blinded to treatment allocation by using
matching tablets and packaging for levothyroxine and
placebo. All study personnel remain blinded for the dur-
ation of the trial through remote analysis of laboratory
results of TSH in the data centre, ensuring the trial stays
double blinded. GPs will remain blinded to treatment al-
location and TSH tests unless otherwise required in the
event of an emergency medical situation. An Interactive
Voice Response System at the data centre allows for in-
dividual emergency allocation information to be released
to an unblinded study physician through 24-h telephone
access. All participants will learn the treatment alloca-
tion within 15 working days of receiving the final visit
and completing all the data to aid in any further treat-
ment decisions with the GP.
All laboratory tests for TSH and fT4 are performed at
the local GP and clinical laboratories. The results in the
treatment phase are uploaded to the independent data
centre which in turn advises the study site on dose titra-
tion through the dedicated trial web portal. The study
team remains unaware of the results of the thyroid func-
tion testing. Additionally, all cooperating GPs were
asked to refrain from additional thyroid function mea-
surements to ensure adequate blinding.
Data collection
Data collection will be performed by study research nurses
at baseline and predetermined follow-up visits at the par-
ticipant’s home or place of residence. All participants are
followed up for a minimum of 1 year with a likely average
of 2 years. Participants are reviewed face-to-face by the
study nurses at recruitment, study baseline, 6–8 weeks,
12 months, 24 months, 36 months and at the final visit.
This personal approach ensures data quality and promotes
participant retention and complete follow-up. In addition,
interim telephone contact or visits (depending on the de-
sire of the patient) are made by study nurses at 6, 18 and
30 months (depending on total duration of follow-up), in-
cluding recording of possible cardiovascular and serious
adverse events (SAEs). For a timeline of assessments and
visits see Table 1.
All study nurses are trained simultaneously on the data
to be assessed. All measuring equipment is calibrated be-
fore the start and annually thereafter to safeguard reliabil-
ity and validity. The Data centre will develop and manage
a dedicated, anonymised trial web portal, including the
electronic case report forms in Dutch and Swiss Standard
German. This portal is based on the dedicated trial web
portal from the TRUST trial to maximize the homogeneity
of data and to allow for pre-planned pooled analysis of the
results. Personal information used for trial logistics is col-
lected and stored in a separate electronic study database
in accordance with legal and ethical requirements.
Data validation checks give study personnel immediate
feedback on missing or out of range values. Logic checks
reduce the possibilities of entering invalid data. Database
validation checks are run routinely and are tracked and es-
calated as appropriate. Data will be locked at the end of the
study according to preregistered lockdown procedures by
the data centre. The data centre will provide the independ-
ent data monitoring committee (IDMC) and the authorities
with (annual) safety reports on the Data.
Outcomes
At 6–8 weeks we expect most patients allocated to
levothyroxine to be biochemically euthyroid, and at
this time point short-term improvements (such as in
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thyroid-related quality of life) will be assessed. By 1
year the medium-term effects of levothyroxine treat-
ment should emerge (such as muscle function). The
long term effects of treatment of SCH will be deter-
mined by assessment over the full course of the
study, with a mean of 2 years treatment duration.
In the screening phase, results from TSH and fT4
tests, exclusion criteria, informed consent for the
screening phase of the study, informed consent for
the trial phase of the study are obtained by the study
nurses.
During the baseline phase of the study the following data
are recorded:
 Participant characteristics: age, sex, ethnicity,
information on alcohol and tobacco use, height.
 Any clinical changes that would violate the inclusion
or exclusion criteria
 Concomitant drugs used: prescribed medication,
over-the-counter non-steroidal anti-inflammatory
drugs and aspirin
 History of disease: Cardiovascular disease including
history of ischaemic heart disease (angina pectoris
or previous myocardial infarction), cerebrovascular
disease (ischaemic stroke, transient ischaemic attack)
or peripheral vascular disease (intermittent
claudication), or any revascularisation procedure for
ischaemic vascular disease. History of atrial
fibrillation, epilepsy, hypertension, diabetes mellitus
or osteoporosis.
 Single lead ECG: to check for atrial fibrillation
 Cognitive function: Mini-mental state examination
(MMSE [11]) score as an indicator of general
cognitive function. This will not be used as an
outcome measure due to insensitivity to change
during the trial.
Table 1 Detailed schedule of assessments
Months of follow up 0
visit
6-8 wks 6m 12m 18m 24m 30m 36m Finala
visitvisit call/visit visit call/visit visit call/visit visit
Participant characteristics & medical history x
Weight, height, waist circumference and BMI x x x
Concomitant medication x x x x x x
Home support x x
Safety and monitoring
Morbidity, mortality, hospitalisation and GP contacts x x x x x x x x
Serious Adverse Events x x x x x x x x
Single-lead ECG (for AF) x x x x x
Drug adherence x x x x x x x x
Outcomes
Thyroid related quality of life (ThyPRO) x x x x
Generic quality of life (EQ-5D-3L) x x x x
Cognitive function
MMSE x
Letter Digit Coding Test x x
Functional ability
ADL (BI), IADL (OARS), falls questionnaire x x
Handgrip strength & 6-meter gait speed x x x
Blood pressure x x x
Fatal and non-fatal cardiovascular events x x x x x x x x
Arthritis complaints x
Treatment Satisfaction (TSQM vII) x
Laboratory analysis
Thyroid function x x x x x x
Haemoglobin x x
Blood samples for biobank x x
athe final visit assessments may substitute for any assessment time between 12 and a maximum of 42 months
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 Home support services: (e.g. home help, meals-on-
wheels, district nursing) and home circumstances
(e.g. living alone, co-habiting, standard or sheltered
housing, or entry to care home)
Primary study endpoints
The main study primary endpoints are mean change
from baseline scores in thyroid-related quality of life and
symptom burden assessed using the hypothyroid symp-
toms scale score and tiredness symptoms scale score on
the thyroid-related quality of life patient-reported out-
come (ThyPRO) [12] at 12 months after recruitment.
The primary analyses will be done in the 80 years and
over group (IEMO and TRUST participants). The results
will be compared through subgroup analysis with those
in the 79 years and under group (TRUST participants)
as a secondary analysis. The ThyPRO is an 85-item
patient-reported outcome measure, evaluating symp-
toms, well-being and function on 85 items summarised
in 14 scales, ranging 0–100, with higher scores repre-
senting more symptoms or impact of disease. For this
study three scales with 19 items are evaluated: Tired-
ness, Hypothyroid physical symptoms and Hyperthyroid
physical symptoms.
Secondary study endpoints
 Generic quality of life: EuroQOL EQ-5D-3 L [13] at
baseline, 6–8 weeks, 12 months and final follow up.
 Thyroid-related quality of life ThyPRO [12] at
baseline, 6–8 weeks and at final follow-up.
 Thyroid-related quality of life: ThyPRO-39 [14] re-
corded at final follow-up (additional 28 questions).
 Executive cognitive function: Letter Digit Coding
Test [LDCT] [15] at baseline and final follow-up.
 Handgrip strength: Jamar hand dynamometer (best
of 3 measures in dominant hand) at baseline,
12 months and final follow up.
 Functional ability: Activities of Daily Living (Barthel
Index [BI] [16, 17]), Instrumental Activities of Daily
Living (Older Americans Resources and Services
[OARS] [18]), 6- m gait speed [19], independent
living status and falls questionnaire at baseline and
final follow up.
 Blood pressure: systolic and diastolic measured at
baseline, 12 months and final follow up
 Height, weight, waist circumference and body mass
index: recorded at baseline, 12 months and final
follow up
 Mortality: all-cause and cardiovascular are requested
through national mortality registries
 Fatal and non-fatal cardiovascular events: including
acute myocardial infarction, stroke, amputations for
peripheral vascular disease and revascularisations for
atherosclerotic vascular disease (including for acute
coronary syndrome and heart failure
hospitalisations).
Additional measurements
 Treatment satisfaction with trial medication:
Treatment Satisfaction Questionnaire for
Medication vII (TSQM [20]) and desire of post-trial
medication continuation recorded at final follow up.
 Arthritis: data regarding joints, skeletal functioning
and arthritis are recorded through an arthritis
questionnaire at final follow up.
 Haemoglobin: measured on a full blood count at
baseline and 12 months.
See Table 1 for detailed schedule of assessments.
Safety
Full details of all Serious Adverse Events (SAEs), Ad-
verse Events (AEs) of special interest (atrial fibrillation,
heart failure, fractures, new diagnosis of osteoporosis),
study treatment withdrawals and ThyPRO hyperthyroid
symptoms are recorded at all visits and telephone con-
tacts. Participants and GPs have 24-h access to an emer-
gency trial phone number operated by a certified
physician for the reporting of SAEs.
Biobank
Blood samples for the IEMO biobank are collected at
baseline (40 ml venous blood) and at 12 months (10 ml
venous blood). The following 19 aliquots (0.75 ml each)
are stored per participant at baseline: 3 EDTA plasma, 1
whole blood, 2 citrated plasma, 1 NaF plasma, 1 buffy
coat, 3 heparin plasma, and 8 serum aliquots. The
12 months bloods are stored in four serum 0.75 ml ali-
quots per participant.
Analyses in the IEMO biobank will be performed in
combination with the TRUST biobank. Both biobanks
are organised by the same biobank committee. The
IEMO biobank will be stored at the Department of Clin-
ical Chemistry of Leiden University Medical Center
(LUMC), the Netherlands. The biobank consists of all
plasma, serum, and DNA material of all randomised
IEMO participants that provide consent for storing bio-
bank material. The Department of Clinical Chemistry of
the LUMC is fully accredited (EN ISO 15189:2012) by
the Dutch Accreditation Council. The Biobank adheres
to all necessary quality assurance standards and legal
guidelines.
Sample size calculation
The total number of participants in all published trials
on SCH before 2017 is 450 across 12 studies, including
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only a small numbers of older people and very heteroge-
neous endpoints across studies.
We aim to study endpoints that are of particular rele-
vance for the oldest old, including endpoints in those
with considerable comorbidity.
Originally, the IEMO 80-plus thyroid trial had set out
to analyse 450 participants with SCH aged 80 years and
over. Additionally, a pre-planned pooled analysis of 900
participants was agreed upon, of which 450 were re-
cruited directly through this study and a subset over the
age of 80 years from the TRUST trial would add another
450 participants, to further increase the statistical power
to detect significant changes in this subgroup. The
power calculations were based on two main study
endpoints:
1. Fatal and non-fatal cardiovascular events.
2. Change in thyroid-related quality of life (ThyPRO
Tiredness and Hypothyroid physical symptoms).
Due to several limiting factors including delays in
starting the studies, caused by difficulties procuring
study medication and matching placebos, it proved im-
possible to reach this number, similar to the experiences
in the TRUST trial [10]. Therefore, in 2015, revised
power calculations were proposed (study protocol
amendment 8, 04/06/2015) and accepted by the funding
agent, sponsor, medical ethical committee (15/07/15)
and competent authority (03/07/2015). These revisions
detailed the change of primary study endpoint cardiovas-
cular events into a secondary study outcome, accepting
the possibility of being underpowered to answer this sec-
ondary endpoint. This allowed the power calculations to
be revised according to the remaining primary outcome
thyroid-related quality of life.
The resulting revised sample-size calculation is based
on the pre-planned pooled analysis of one of the
co-primary endpoints of thyroid-related quality of life
(ThyPRO Hypothyroid physical symptoms and Tired-
ness scale score). According to previous studies applying
the ThyPRO, a study should be adequately powered for
at least a difference of 9 points to be clinically meaning-
ful. Using an expected standard deviation of the differ-
ence of 26 [21] and a power of 80%, 132 participants are
required per trial group adding to a total of 264 partici-
pants to be included in the combined 80-plus analyses.
For all secondary continuous endpoints this sample size
is deemed large enough to provide statistically robust re-
sults. For the secondary endpoints on cardiovascular
events and mortality the possibility of being underpow-
ered is accepted.
Over a recruitment period of almost 3 years the
TRUST trial recruited 737 participants to the trial of
which 146 participants were aged 80 and over. Assuming
10% loss to follow-up in both trials a projected 145 add-
itional participants will be recruited in the IEMO trial.
The follow up phase of the trial is expected to be
complete in May 2018 with one additional month of
SAE recording.
Data analysis
The data centre (Robertson Centre for Biostatistics,
Glasgow, ISO 9001/2008 certified) is responsible for
writing, implementing and revising a statistical analysis
plan that is agreed upon before locking the study data-
base and will have full access to the final study database
for the planned analyses. A copy of the statistical ana-
lysis plan is appended to this manuscript as Add-
itional file 1. All analyses are based on a modified
intention-to-treat principle and the primary time-point
for analysis is after 12 months of treatment. The main
analyses will be based on the combined IEMO and
TRUST 80-plus participants (n = 291).
Analyses will be presented separately for:
– the IEMO 80-plus participant cohort (n = 145)
– the TRUST 80-plus participant subset (n = 146)
– the combined IEMO and TRUST 80-plus partici-
pants compared with the TRUST 80-minus partici-
pants (n = 291 vs n = 591)
Summary information for all participants and between
the treatment groups will be made available. Similar to
the TRUST trial [10], continuous variables measured at
baseline and follow-up will be analysed at each time
point comparing treatment groups adjusting for stratifi-
cation variables and baseline levels of the same variable
using analysis of covariance. Additionally, repeated mea-
sures regression analysis will be performed with regards
to the primary time-point and final assessment for each
participant. For calculating ThyPRO scores, raw total
scores containing valid missing items will be scaled to
maintain the maximum possible score. Clinical outcome
data will be analysed using time-to-first-event Cox pro-
portional hazards regression analysis in models that con-
tain the randomised treatment allocation and
stratification variables as covariates. Treatment effect
will be analysed using the Wald-test and corresponding
point estimates and 95% confidence intervals for the
hazard ratio for treatment will be estimated. The as-
sumption of proportionality of hazards will be tested.
Analysis of the primary outcomes will be performed in
the modified intention to treat (ITT) population, based
on participants with data available on the outcome of
interest. The ITT population will be used for analyses
on efficacy and safety. In addition, analyses using mixed
effects models and multiple imputations will be used for
sensitivity analysis. The per protocol population will also
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be used for all primary and secondary outcomes as ex-
ploratory analyses.
Owing to the intended similarities in study design be-
tween the IEMO 80-plus thyroid trial and the TRUST
trial, the data allow for a pooled subgroup analysis of the
TRUST and IEMO 80-plus participants compared with
the TRUST 80-minus participants. Outcome differences
between these groups will highlight the additional clin-
ical merits or adverse effects of levothyroxine replace-
ment therapy for older participants aged 80 and over.
Other pre-planned subgroup analyses include: baseline
TSH in two groups (< 10/≥10 mIU/L) or in three groups
(< 7/7–9.99/≥10 mIU/L), sex (male/female). However, we
accept that our study will be underpowered for some of
the smaller subgroups, such as male participants, TSH
above 10.0 and below 19.9 mIU/L. We should however
have sufficient statistical power in the combined analysis
to detect beneficial effects in the larger or dominant sub-
groups, such as female and TSH in the range above 4.6
and below 10.0 mIU/L.
Monitoring and committees
To secure the highest quality of participant care and
safety, the careful titration algorithm avoids the possibility
of prolonged periods of levothyroxine over-replacement.
Similarly, the system guards against participants develop-
ing overt hypothyroidism that might require open-label
levothyroxine use.
All SAEs, AEs and AEs of special interest are recorded,
notified, assessed, reported, analysed and managed in ac-
cordance with the Medicines for Human Use (Clinical
Trials) Regulations 2004 and the study protocol. All
events are followed up until resolution or stabilization
occurs, and are assessed for seriousness, expectedness
and causality by the chief investigator. Serious adverse
events are reported to the sponsor by thorough record-
ing in the eCRF and to the local accredited Medical Eth-
ics Committee and competent authority. Annually and
at the end of the trial 100% study monitoring visits are
conducted by independent clinical research associates, in
accordance with the Netherlands Federation of Univer-
sity Medical Centres’ report ‘Kwaliteitsborging van
Mensgebonden onderzoek’. All important decisions
made leading to protocol modifications are communi-
cated to all relevant parties, including the trial registry,
ethical committees and competent authorities.
All main decisions for the study were made by the
steering group. Its members are: Dr. Simon P. Mooijaart,
Dr. Jacobijn Gussekloo, Dr. Olaf M. Dekkers, Dr. Jan
Smit, Dr. J.Wouter Jukema, Dr. Anton. J.M. de Craen
(Leiden, the Netherlands, Deceased).
Each national site was supervised by a local organising
committee and Principle Investigator. For the Netherlands
the organising committee was: Dr. Simon P. Mooijaart
(PI), Dr. Rosalinde K.E. Poortvliet, Dr. Iris Postmus,
Robert S. Du Puy, MSc, Professor Robin. P. Peeters, Pro-
fessor Bruce. H.R. Wolffenbuttel and Dr. Barbara. C. van
Munster. For Switzerland the organising committee was:
Professor N. Rodondi (PI) and Dr. Manuel Blum,
An Independent Data Monitoring Committee (IDMC)
assesses safety data in order to protect the ethical and
safety interests of the participants recruited into the
study, while safeguarding, as far as possible, the scientific
validity of the study. The IDMC reviews annual safety
and efficacy data and may request additional data if con-
sidered necessary. The IDMC meets at least once a year
and is composed of medical experts and a biostatistician
without any involvement in the study as investigators or
as study participant care physicians. The committee is
empowered to make a recommendation on early stop-
ping when there is overwhelming evidence of benefit for
the primary outcome or when it considers there is ad-
equate evidence of harm. The IDMC members are: Pro-
fessor Gary Ford (Chair; Chief Executive Officer of the
Oxford Academic Health Science Network, Oxford),
Professor Thompson G Robinson (University Hospitals
of Leicester NHS Trust, Department of Cardiovascular
Sciences, Leicester Royal Infirmary, Leicester), Professor
Colin Dayan (Institute of Molecular and Experimental
Medicine, Cardiff University School of Medicine, Heath
Park, Cardiff ), Professor Kathleen Bennett (Department
of Pharmacology and Therapeutics, Trinity Centre for
Health Sciences, St James’s Hospital, Dublin).
A study Endpoint Committee, blinded to treatment al-
location, provides independent and unbiased review of
clinical endpoint events which occur during the study,
ensures unified and unambiguous events evaluation
practices across the study and compensates for regional
diversity in medical practice at the site of endpoint
evaluation and classification. All causes of death, stroke,
myocardial infarction and heart failure hospitalisations
are potential endpoints to be reviewed on the data sup-
plied through the eCRF and if necessary acquired source
documentation. The Endpoint Committee members are:
Professor Peter Langhorne (Chair; Professor of Stroke
Care, Institute of Cardiovascular and Medical Sciences,
University of Glasgow), Professor J Wouter Jukema
(Vice-chair; Professor of Cardiology, Leiden University
Medical Center, The Netherlands), Dr. Tin Hai Collet
(Department of Ambulatory Care and Community
Medicine, University of Lausanne, Switzerland), Profes-
sor Olaf M Dekkers Leiden University Medical Center,
The Netherlands) and Dr. Anne Marie O’Flynn (Depart-
ment of Epidemiology and Public Health, UCC, Ireland).
A TRUST/IEMO Biobank committee supervises the
storage and analysis of the biobank samples. Members
are: Professor Patricia M. Kearney, Dr. H. Anette van
Dorland (Bern, Switzerland), Dr. Wendy P.J. den Elzen.
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Each national study site is supervised by a local spon-
sor, responsible for the oversight of the clinical trial and
supplying proper insurance to cover any liabilities during
and after the trial arising from trial conduct and partici-
pation. The sponsors is not involved in the preparation,
or approval of any scientific outputs.
Dissemination
This study is well suited to promote effective dissemin-
ation of the results and implications. Arrangements re-
garding sharing of data and joint publication are laid
down in a Memorandum of Understanding between the
TRUST trial and IEMO 80-plus thyroid trial project
group. Due to its role as a knowledge centre with an
education and research program in the field of ageing,
vitality and geriatric medicine, the Leiden Academy on
Vitality and Ageing is well placed to play a coordinating
role in the dissemination activities. Schildklier Organisa-
tie Nederland, the patient advocacy group, will closely
collaborate with the study team to help align the study
outputs with the patients and public need.
The Institute for Evidence-based Medicine in Old Age
(the Netherlands) is ideally placed to ensure that the re-
sults of the study are considered by relevant profes-
sionals, and will be included in the leading clinical
guidelines. In cooperation with the Cochrane collabor-
ation the results of the trial will be offered for the update
of the Cochrane systematic review of treatment of sub-
clinical hypothyroidism, allowing for independent scien-
tific interpretation, placing results in context and
maximising understanding of the implication of the trial.
To comply with the general social responsibility asso-
ciated with clinical research, the trial results will be pro-
actively disseminated to the general public and key
public health stakeholders through established media
networks.
Discussion
In the latest Cochrane review of levothyroxine replace-
ment therapy for SCH (12 studies, only 491 participants
in total) most studies excluded those who suffered from
multimorbidity, none of the studies reported on oldest
old separately and two trials excluded those over the age
of 80 years [22]. Robust evidence for the potential clin-
ical merits or adverse effects in 80-plus persons with
SCH is greatly needed to help guide clinical practice.
The IEMO 80-plus thyroid trial is a representative ran-
domised controlled trial on levothyroxine treatment for
SCH, with representative 80-plus persons and a wide
range of characteristics and morbidities, studying
end-points that are relevant to the older population and
clinical practice. The combined analysis of participants
in the IEMO 80-plus thyroid trial with those aged over
80 who participated in the TRUST trial will provide the
largest experimental evidence base on the multimodal
effects of levothyroxine treatment in 80-plus persons to
date. Trial results are expected to be publicly dissemi-
nated in the fall of 2018.
Appendix 1: Patient Information leaflet for
screening
Thyroid hormone replacement for older persons with
mild thyroid dysfunction.
In the past 3 years blood was drawn at your general
practice office or in the hospital. The results showed that
you may be eligible for participating in the IEMO 80+
Thyroid Trial. For this reason your general practitioner
or hospital specialist sends you this letter and the infor-
mation leaflet regarding this research study.
1. What is the purpose of the research study?
Thyroid hormone has many important functions in
the human body, for example supporting the correct
function of the muscles, circulation, the brain and me-
tabolism. When a shortage of thyroid hormone is
present, bodily functions may not work optimally.
The results of one of your blood tests from the past
suggest that you may have mild thyroid dysfunction
(subclinical hypothyroidism). This is when thyroid hor-
mone levels are within the normal laboratory limits, but
signs are present that the body is urging the thyroid
gland to work harder. This is usually a chance finding.
This particular blood test result is common in older per-
sons: of all persons aged 65 years and over 1 in 6 may
have subclinical hypothyroidism. It is currently unknown
whether it is beneficial to treat subclinical
hypothyroidism with artificial thyroid hormone. The
IEMO 80+ Thyroid Trial was set out to investigate this
problem. The purpose of the IEMO 80+ Thyroid Trial is
to find out what effects (good and bad) thyroxine re-
placement has in older people with subclinical
hypothyroidism. In total 150 Dutch participants will par-
ticipate in the IEMO 80+ Thyroid Trial.
2. What drug will be investigated?
We investigate the effect of synthetic thyroid hormone
(Levothyroxine) in older persons with subclinical
hypothyroidism. This thyroid hormone is given by tablet
orally (by mouth). We will compare the effects of the
thyroid hormone tablets with effects of a placebo tablet.
The placebo tablets contain no active drug, but are iden-
tical in look, taste and smell.
3. How will the research study be conducted?
You have been asked to take part in this study because
your recent screening blood test has suggested that you
may have subclinical hypothyroidism. In some persons
subclinical hypothyroidism corrects over time, whilst in
other persons a clear shortage of thyroid hormone is
identified. For this reason the first phase (the selection
phase) will determine whether you have a persistent
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subclinical hypothyroidism. Only when this is the case,
are you eligible for the second phase of the study (the
treatment phase).
If you agree to participate in the selection phase of the
study we ask you to complete and sign the consent form
and send this in the enclosed envelope to the study cen-
ter in the Leiden University Medical Centre. The study
center will return a laboratory form and will ask you to
visit your general practice laboratory or hospital research
facility for a screening visit within 2 weeks. In this
screening visit a blood test will be performed to assess
the levels of thyroid hormone. The results of this test
will be send to the research center in the Leiden Univer-
sity Medical Centre. If you are unable to visit the labora-
tory, please contact the study center. They will arrange
for a laboratory nurse to visit you at home.
If the results from the screening test indicate that you
are not eligible for the treatment phase, the study center
will inform you in writing with the screening results and
an explanation. The screening result will be shared with
your general practitioner or hospital specialist.
If the results from the screening tests are satisfactory
you will be invited to take part in the treatment phase of
the study. A research nurse will contact you with the
screening results and to plan an appointment for a home
visit. During this home visit the research nurse will ex-
plain the treatment phase of the research study and you
may decide to participate in the treatment phase.
If you decide to take part, you will be asked to
complete and sign a second consent form. After signing
the form some medical questions will be asked (includ-
ing general questions regarding health, medication use
and quality of life) as well as some additional measure-
ments taken (including blood pressure, heart rhythm
and grip strength).
After the home visit a computer will randomly allocate
you to either the levothyroxine or placebo treatment
group. The chance of allocation to either group is equal
(50%). The study drug will be taken daily, at least
30 min before breakfast, during a maximum of 2 years.
A research nurse will perform home visits at the start
of the research study, after 6–8 weeks, after 12 months
and after 24 months. We will ask you to visit the general
practice laboratory before every home visit to assess thy-
roid hormone levels.
4. What are the possible risks and benefits in
participating?
It is not certain whether you will gain personal benefit
from participating in the research study. After all, the
purpose of this research study is to assess whether treat-
ment with levothyroxine provides important benefits. A
potential benefit is that your thyroid function will be as-
sesses regularly, both in the screening and treatment
phase. For future older persons with subclinical
hypothyroidism the research study may yield important
information. The blood measurements taken will most
likely not result in harmful effects.
5. What happens if you decide not to participate in
the research study?
Your participation is entirely voluntary and you are
not in any way obliged to take part. You decide whether
you want to participate. If you decide not to participate,
no further action is required, and you are not required
to provide a reason for not participating. If you do de-
cide to participate, you reserve the right to withdraw
from the research study at any given time without pro-
viding a reason to do so. Whether you decide to partici-
pate or not will in no way affect the standard of care you
receive or the relationship you have with your general
practitioner or hospital specialist.
6. Will the research study result in additional ex-
penses/provide compensation?
No. You will not be charged for expenses related to
the study medication or blood tests. Participating in this
research study will not affect your policy excess for med-
ical insurance. No compensation is provided for partici-
pating in the research study.
7. Further information?
Should you have any additional questions regarding
the research study you are welcome to contact the
IEMO secretary, telephone 071–526 84 93, or the cen-
tral study coordinator: The Institute for Evidence-Based
Medicine in Old Age | IEMO.
Email: iemo_schildklierstudie@lumc.nl. More informa-
tion can be found on the study website:
www.iemoschildklierstudie.nl
For questions or problems you may also contact the
independent general practitioner, Dr. Niels H. Cha-
vannes, telephone 071–526 84 44, n.h.chavanne-
s@lumc.nl. He is up-to-date with all proceedings of the
trial, but is not involved with the conduct.
8. Appendices
1. Informed consent form.
2. envelope.
Appendix 2: Patient Information leaflet for
randomisation
Thyroid hormone replacement for older persons with
mild thyroid dysfunction
Several weeks ago your general practitioner or hospital
specialist has invited you for a blood screening test. Ac-
cording to the test results you still have mild thyroid dys-
function (subclinical hypothyroidism). You are being
invited to take part in a research study:
The IEMO 80+ Thyroid Trial
In this leaflet you’ll find detailed information regarding
the research study. Please take your time to review the
contents carefully and discuss these with your partner,
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friends or family. Should you have additional questions
you are welcome to discuss these with your general prac-
titioner, a researcher or the research nurse. Additionally
you may contact the independent general practitioner,
who knows a lot about the study, but is not involved with
the conduct. Contact information can be found on the
final page.
1. What is the purpose of the research study?
Thyroid hormone has many important functions in
the human body, for example supporting the correct
function of the muscles, circulation, the brain and me-
tabolism. When a shortage of thyroid hormone is
present, bodily functions may not work optimally.
The results of one of your blood tests from the past
suggest that you may have mild thyroid dysfunction
(subclinical hypothyroidism). This is when thyroid hor-
mone levels are within the normal laboratory limits, but
signs are present that the body is urging the thyroid
gland to work harder. This is usually a chance finding.
This particular blood test result is common in older per-
sons: of all persons aged 65 years and over 1 in 6 may
have subclinical hypothyroidism. It is currently unknown
whether it is beneficial to treat subclinical
hypothyroidism with artificial thyroid hormone.
Having subclinical hypothyroidism is associated with
slightly higher odds of developing cardiovascular dis-
eases. Earlier small scale research demonstrated that
treatment with synthetic thyroid hormone may provide
beneficial effects on the circulation in older persons with
subclinical hypothyroidism. Alternatively, synthetic thy-
roid hormone treatment may also result in unwanted
side effects. Both the good and bad effects of thyroid
hormone treatment have not been proven to this date.
The purpose of the IEMO 80+ Thyroid Trial is to find
out what effects (good and bad) thyroxine replacement
has in older people with subclinical hypothyroidism.
The research study has a specific aim to prevent car-
diovascular diseases, and to improve the quality of life
(for example by alleviating tiredness complaints), muscle
strength and brain function. In total 150 persons in the
Netherlands will take part in the IEMO 80+ Thyroid
Trial. ‘IEMO 80+’ means that the research study is per-
formed in persons aged 80 years and older. IEMO is an
abbreviation for the Institute for Evidence-Based Medi-
cine in Old Age, the institute responsible for coordinat-
ing the research study.
2. What drug will be investigated?
We investigate the effect of synthetic thyroid hormone
(Levothyroxine) in older persons with subclinical
hypothyroidism. This synthetic thyroid hormone is iden-
tical to the thyroid hormone produced by the human
body and is the standard treatment when a definite
shortage of thyroid hormone is identified in the blood.
This thyroid hormone is given by tablet orally (by
mouth). We will compare the effects of the thyroid hor-
mone tablets with effects of a placebo tablet. The pla-
cebo tablets contain no active drug, but are identical in
look, taste and smell. You will not be informed which of
the two treatments you will receive. The study nurses
are also unaware of your allocation.
You will start with 1 tablet, that will contain either 50
micrograms of levothyroxine (or 25 micrograms if your
weight is below 50 kg or have a history of coronary stric-
tures) or placebo. After 6–8 weeks all participants will
have their blood hormone levels analysed. Based on
these results a decision is made to change the treatment
dose. If the laboratory results indicate a change in treat-
ment dose is warranted a research nurse will explain this
to you. From this point annual blood tests will monitor
the response to the treatment (after 12 and 24 months).
3. How will the research study be conducted?
You have been asked to take part in this study because
your recent screening blood test has suggested that you
may have subclinical hypothyroidism.
If you agree to participate in the selection phase of the
study we ask you to complete and sign the consent form
and send this in the enclosed envelope to the study cen-
ter in the Leiden University Medical Centre. We ask
your permission to store additional blood samples for fu-
ture research on blood and hereditary materials (DNA)
that may influence the effects of thyroid hormone on
bodily functions (such as the circulation, muscle
strength, memory problems or frailty). The DNA will be
isolated from the blood and stored for future research.
This blood sample (equivalent to 8 teaspoons) will be
taken during the first home visit. Other research not re-
lated to this research study will not have access to the
stored blood and DNA samples and any information in
the samples cannot be retraced to individual persons. If
you object to the storage of blood and DNA you may
choose not to participate in this particular portion of the
trial.
After signing the consent form some medical ques-
tions will be asked (including general questions regard-
ing health, medication use and quality of life) as well as
some additional measurements taken (including blood
pressure, heart rhythm and grip strength). This home
visit will take approximately1 to 1.5 h.
After the home visit a computer will randomly allocate
you to either the levothyroxine or placebo treatment
group. The chance of allocation to either group is equal
(50%). The study drug will be taken daily, at least
30 min before breakfast, during a maximum of 2 years.
A research nurse will perform home visits at the start
of the research study, after 6–8 weeks, after 12 months
and after 24 months. We will ask you to visit the general
practice laboratory before every home visit to assess thy-
roid hormone levels.
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4. What is expected of you?
If you decide to participate in the research study, you
will be asked:
 To take between 1 and 3 tablets, once every day, in
the morning
 To attend home visits with a research nurse for
measurements
 To visit the general practice laboratory for thyroid
hormone tests (after 6–8 weeks, after 12 months
and after 24 months).
There are no lifestyle or dietary restrictions in this re-
search study. Data from your medical records at the gen-
eral practice office or hospital specialist will be collected.
Your general practitioner or hospital specialist will be in-
formed of your participation in the study.
5. Are there other treatment options?
There are no other treatment options for mild thyroid
dysfunction (subclinical hypothyroidism).
6. What are the possible side effects?
Side effects from levothyroxine treatment are only
rarely seen, particularly if blood tests are done regularly
and adjustments to levothyroxine dosages are made to
keep thyroid hormone levels in the normal range. If
levothyroxine is prescribed in too high dosages there is a
risk of side effects such as heart palpitations, tremors,
sweating, feeling agitated, tiredness and shortness of
breath and chest pains. Overmedication may cause leg
swelling and there may be an increased risk of thinning
of the bones (osteoporosis) and fractures.
If you suffer from epilepsy overmedication with thy-
roid hormone may result in an increased risk of seizures.
If you are on an anticoagulant it is possible that the
dose may need to be adjusted to prevent your blood be-
coming too thin.
If you are allocated to the inactive tablets (placebo) there
is a risk that the thyroid gland may slow down further,
and they may develop symptoms of an underactive thy-
roid, including tiredness and lethargy. Should this develop
during the research study the blood tests will identify an
underactive thyroid and your general practitioner or hos-
pital specialist will be consulted for starting treatment.
7. What are the possible risks and benefits in
participating?
It is not certain whether you will gain personal benefit
from participating in the research study. After all, the pur-
pose of this research study is to assess whether treatment
with levothyroxine provides important benefits. A potential
benefit is that your thyroid function will be assesses regu-
larly, both in the screening and treatment phase. For future
older persons with subclinical hypothyroidism the research
study may yield important information. The blood measure-
ments taken will most likely not result in harmful effects.
8. What happens if you decide not to participate in
the research study?
Your participation is entirely voluntary and you are
not in any way obliged to take part. You decide whether
you want to participate. If you decide not to participate,
no further action is required, and you are not required
to provide a reason for not participating. If you do de-
cide to participate, you reserve the right to withdraw
from the research study at any given time without pro-
viding a reason to do so. Whether you decide to partici-
pate or not will in no way affect the standard of care you
receive or the relationship you have with your general
practitioner or hospital specialist.
9. What happens after the research study is
finished?
When the treatment phase of the study completes, the
results will be analysed by the coordinating researchers.
This process will last several months after the last par-
ticipant has finished the duration of the study. You and
your general practitioner will be informed in writing of
your results during the study, and whether you were al-
located to the levothyroxine or placebo group. Based on
this information you and your general practitioner may
discuss whether further treatment with levothyroxine is
in your best interest.
10. Are you insured during the research study?
All participants of the research study are covered by
insurance for potential damages resulting from the
study, both during the study period and within 4 years
of ending the study. At the end of this letter you will
find the insured amounts, exceptions and contact infor-
mation of the insurance agency.
11. What if new information becomes available?
The data from all study participants are reviewed at
fixed time points by a specially installed independent
commission. If the safety or quality of life of the partici-
pants is in jeopardy, this commission is entitled to stop
the research study. The study team will contact you dir-
ectly should this occur.
12. What happens to the data collected?
In this research study data from interviews, question-
naires and measurements will be collected. As well as
blood sample analysis. All data and materials collected will
be handled and stored confidentially. Only the lead inves-
tigator will have access to personal information.
Unauthorized personnel will have no access to your data.
The results from this research study will be published in
scientific journals; the data will not be traceable to individ-
ual persons. Anonymised research data will be made avail-
able to the IEMO 80+ Thyroid Trial investigators.
13. Will your general practitioner/hospital special-
ist be informed of study participation?
We think it is important that your general practitioner
or hospital specialist is informed when study medication
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is given. For this reason we will inform your general
practitioner or hospital specialist in writing of your par-
ticipation. A specific section of the consent form ex-
plains this in more detail. It is not possible to participate
in the research study without this consent.
14. Will the research study result in additional ex-
penses/provide compensation?
No. You will not be charged for expenses related to
the study medication or blood tests. Participating in this
research study will not affect your policy excess for med-
ical insurance. No compensation is provided for partici-
pating in the research study.
15. Who has reviewed the study?
The Medical Ethics Committee from the Leiden Uni-
versity Medical Centre has reviewed and approved the
research study.
16. Further information?
Should you have any additional questions regarding
the research study you are welcome to contact the
IEMO secretary, telephone 071–526 84 93, or the cen-
tral study coordinator: The Institute for Evidence-Based
Medicine in Old Age | IEMO.
Email: iemo_schildklierstudie@lumc.nl. More infor-
mation can be found on the study website:
www.iemoschildklierstudie.nl
For questions or problems you may also contact the
independent general practitioner, Dr. Niels H. Cha-
vannes, telephone 071–526 84 44, n.h.chavanne-
s@lumc.nl. He is up-to-date with all proceedings of the
trial, but is not involved with the conduct.
Additional files
Additional file 1: Statistical analysis plan. (PDF 114 kb)
Additional file 2: Participant consent form for screening. (PDF 68 kb)
Additional file 3: Participant consent form randomisation. (PDF 83 kb)
Abbreviations
AE: Adverse event; eCRF: Electronic case report form; fT4: Free thyroxine;
GP: General practitioner; IDMC: Independent Data Management Committee;
IEMO: Institute for evidence-based medicine in old age; RCT: Randomised
controlled trial; SAE: Serious adverse event; SCH: Subclinical hypothyroidism;
ThyPRO: Thyroid-related quality of life patient-reported outcome;
TRUST: Thyroid hormone replacement for untreated older adults with
subclinical hypothyroidism - a randomised placebo controlled trial;
TSH: Thyroid stimulating hormone
Acknowledgements
The authors would like to thank K. Broekhuizen and C. van Beuzekom for
their significant investments in an earlier phase of this research. Merck KGaA
provided the study medication and matching placebos without recompense.
The logistics of handling and distributing the study medication was done by
Mawdsley Brooks & Co. Randomisation and providing an electronic data
capture and safeguarding system was performed by the Robertson Centre
for Biostatistics. We also thank all members of the Independent Data
Monitoring Committee.
Sponsor contact information: Trial Sponsor: Leiden University Medical Center,
Address Albinusdreef 2, 2333 ZA, Leiden, Telephone: + 3171 5269111.
Funding
The IEMO 80-plus thyroid trial has been peer reviewed and approved for
funding under the ZonMw programme Evidence-based Medicine in Old
Age, ZonMW programme number: 627001001. The Swiss part of the trial was
supported by grants from the Swiss National Science Foundation to Dr.
Rodondi (SNF 320030–150025 and 320030–172676).
The TRUST study was supported by a research grant from the European
Union FP7-HEALTH-2011 programme - Investigator-driven clinical trials for
therapeutic interventions in elderly populations. Grant agreement number
278148. Study medication was supplied free of charge by Merck KGaA.
Availability of data and materials
The authors welcome proposals for joint use of the study data after the
planned publications of the study data have been completed. Proposals
should be sent to the corresponding author.
Authors’ contributions
All authors have fulfilled the following: 1. made substantial contributions to
conception and design, or acquisition of data, or analysis and interpretation
of data; 2. been involved in drafting the manuscript or revising it critically for
important intellectual content; 3. given final approval of the version to be
published. Each author should have participated sufficiently in the work to
take public responsibility for appropriate portions of the content; and 4.
agreed to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved. Contributions to the TRUST trial
have been specified elsewhere [10]; most importantly DJS (head PI), NR, PMK,
RGJW, JG (national PI’s), IF (lead statistician). Notable additional contributions
for the IEMO 80 + trial and the over-80 combined analyses: Study conception
and design: SPM (lead), JG, RGJW, DJS; lead on interpretation of data for the
work AND Lead in finalising the manuscript: SPM; acquired funding for IEMO
80+ study: SPM (lead), RPP, BCvM, BHRW, JG, RGJW. Primary Investigator
Netherlands: SPM (lead); Primary Investigator Switzerland: NR; IF Director of
Clinical. Trials Unit, University of Glasgow; Drafting of initial manuscript: RDP,
IP, JG.
Ethics approval and consent to participate
For the Netherlands site the study was approved by the Medical Ethical
Committee on Research Involving Human Subjects (CCMO). For the
Switzerland site the study was approved by the Bern ethical board and by
the Swiss competent authority for drugs (Swissmedic). All participants
provided written informed consent for both the screening and the
participation phase (Additional files 2 and 3).
Consent for publication
Not applicable.
Competing interests
ZonMw and the Swiss National Science Foundation, as the funder, had no
role in the design and conduct of the study nor in the preparation, review
or approval of the manuscript. Merck KGaA provided the study medication
and matching placebos without recompense. Merck KGaA was not involved
in the design, funding or execution of the study or manuscript. The authors
declare that they have no competing interest.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Public Health and Primary Care, Leiden University Medical
Center, Leiden, the Netherlands. 2Department of Gerontology and Geriatrics
(C7-Q), Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The
Netherlands. 3Institute for Evidence-based Medicine in Old age, Leiden, the
Netherlands. 4Geriatric Medicine, Institute of Cardiovascular and Medical
Sciences, University of Glasgow, Glasgow, UK. 5Department of General
Internal Medicine, Bern University Hospital, University of Bern, Bern,
Switzerland. 6Department of Clinical Chemistry and Laboratory Medicine,
Leiden University Medical Center, Leiden, the Netherlands. 7Department of
Internal Medicine, Erasmus University Medical Centre, Rotterdam, the
Netherlands. 8Department of Internal Medicine, Academic Medical Center,
Du Puy et al. BMC Endocrine Disorders  (2018) 18:67 Page 13 of 14
Amsterdam, the Netherlands. 9Department of Endocrinology, University
Medical Center Groningen, University of Groningen, Groningen, the
Netherlands. 10Department of Public Health, University of Copenhagen,
Copenhagen, Denmark. 11Center for Healthy Aging, University of
Copenhagen, Copenhagen, Denmark. 12Department of Epidemiology and
Public Health, University College Cork, Cork, Ireland. 13Robertson Centre for
Biostatistics, University of Glasgow, Glasgow, UK. 14Department of Internal
Medicine, Copenhagen University Hospital Herlev, Gentofte, Denmark.
15Department of Cardiology, Leiden University Medical Center, Leiden, the
Netherlands. 16Department of Endocrinology and metabolic disorders,
Leiden University Medical Center, Leiden, the Netherlands. 17Radboud
University Medical Center, Nijmegen, the Netherlands. 18Institute of Primary
Health Care (BIHAM), University of Bern, Bern, Switzerland.
Received: 3 May 2018 Accepted: 3 August 2018
References
1. Jones DD, May KE, Geraci SA. Subclinical thyroid disease. Am J Med. 2010;
123(6):502–4.
2. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-
Pollack R, Singer PA, Woeber KA, American Association of Clinical E, et al.
Clinical practice guidelines for hypothyroidism in adults: cosponsored by
the American Association of Clinical Endocrinologists and the American
Thyroid Association. Endocr Pract. 2012;18(6):988–1028.
3. Biondi B, Cooper DS. The clinical significance of subclinical thyroid
dysfunction. Endocr Rev. 2008;29(1):76–131.
4. Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP,
Sattar N, Aubert CE, Aujesky D, Bauer DC, et al. Thyroid hormone therapy for
older adults with subclinical hypothyroidism. N Engl J Med. 2017;376(26):
2534–44.
5. Devdhar M, Drooger R, Pehlivanova M, Singh G, Jonklaas J. Levothyroxine
replacement doses are affected by gender and weight, but not age.
Thyroid. 2011;21(8):821–7.
6. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum
thyroid-stimulating hormone concentration and morbidity from
cardiovascular disease and fractures in patients on long-term thyroxine
therapy. J Clin Endocrinol Metab. 2010;95(1):186–93.
7. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp
RG. Thyroid status, disability and cognitive function, and survival in old age.
JAMA. 2004;292(21):2591–9.
8. Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, Asvold BO,
Iervasi G, Imaizumi M, Collet TH, et al. Subclinical hypothyroidism and the risk
of coronary heart disease and mortality. JAMA. 2010;304(12):1365–74.
9. Jansen SW, Akintola AA, Roelfsema F, van der Spoel E, Cobbaert CM,
Ballieux BE, Egri P, Kvarta-Papp Z, Gereben B, Fekete C, et al. Human
longevity is characterised by high thyroid stimulating hormone secretion
without altered energy metabolism. Sci Rep. 2015;5
10. Stott DJ, Gussekloo J, Kearney PM, Rodondi N, Westendorp RG, Mooijaart S,
Kean S, Quinn TJ, Sattar N, Hendry K, et al. Study protocol; thyroid hormone
replacement for untreated older adults with subclinical hypothyroidism - a
randomised placebo controlled trial (TRUST). BMC Endocr Disord. 2017;17(1):6.
11. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician. J
Psychiatr Res. 1975;12(3):189–98.
12. Watt T, Hegedus L, Groenvold M, Bjorner JB, Rasmussen AK, Bonnema SJ,
Feldt-Rasmussen U. Validity and reliability of the novel thyroid-specific
quality of life questionnaire, ThyPRO. Eur J Endocrinol. 2010;162(1):161–7.
13. Rabin R, Gudex C, Selai C, Herdman M. From translation to version
management: a history and review of methods for the cultural adaptation of
the EuroQol five-dimensional questionnaire. Value Health. 2014;17(1):70–6.
14. Watt T, Bjorner JB, Groenvold M, Cramon P, Winther KH, Hegedus L,
Bonnema SJ, Rasmussen AK, Ware JE Jr, Feldt-Rasmussen U. Development
of a short version of the thyroid-related patient-reported outcome ThyPRO.
Thyroid. 2015;25(10):1069–79.
15. Smith A. The symbol digit modalities test. A neuropsychological test for
economic screening of learning and other cerebral disorders. Learn Disord.
1968;3:82–91.
16. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel index. Md State
Med J. 1965;14:61–5.
17. Quinn TJ, Langhorne P, Stott DJ. Barthel index for stroke trials: development,
properties, and application. Stroke. 2011;42(4):1146–51.
18. George LK, Fillenbaum GG. OARS methodology. A decade of experience in
geriatric assessment. J Am Geriatr Soc. 1985;33(9):607–15.
19. Bohannon RW. Measurement of gait speed of older adults is feasible and
informative in a home-care setting. J Geriatr Phys Ther (2001). 2009;32(1):22–3.
20. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of
the treatment satisfaction questionnaire for medication (TSQM version II)
among outpatient pharmacy consumers. Value Health. 2005;8(Suppl 1):S9–s24.
21. Winther KH, Cramon P, Watt T, Bjorner JB, Ekholm O, Feldt-Rasmussen U,
Groenvold M, Rasmussen AK, Hegedus L, Bonnema SJ. Disease-specific as
well as generic quality of life is widely impacted in autoimmune
hypothyroidism and improves during the first six months of levothyroxine
therapy. PLoS One. 2016;11(6):e0156925.
22. Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement
for subclinical hypothyroidism. Cochrane Database Syst Rev. 2007;3:
CD003419.
Du Puy et al. BMC Endocrine Disorders  (2018) 18:67 Page 14 of 14
